Ono Pharmaceutical Co., Ltd.’s consolidated financial results for 2025 (fiscal year ending March 2026) show sales of 486.9 billion yen (up 5.9% YoY), core operating profit of 112.7 billion yen (up 21.7% YoY), and net income attributable to owners of the parent of 90.4 billion yen (up 14.5% YoY). The forecasts for 2026 project sales of 515.8 billion yen (down 11.8%), operating profit of 137.1 billion yen (down 9.6%), and net income of 103.5 billion yen (down 14.5%).<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4528","jir_company_name":"Unknown","jir_importance":"\u2605\u2605\u2605\u2605\u2605","jir_publication_date":"2026-05-08","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/05\/4528-20260508-02.pdf","jir_short_summary":"Ono Pharmaceutical Co., Ltd.'s consolidated financial results for 2025 (fiscal year ending March 2026) show sales of 486.9 billion yen (up 5.9% YoY), core operating profit of 112.7 billion yen (up 21.7% YoY), and net income attributable to owners of the parent of 90.4 billion yen (up 14.5% YoY). The forecasts for 2026 project sales of 515.8 billion yen (down 11.8%), operating profit of 137.1 billion yen (down 9.6%), and net income of 103.5 billion yen (down 14.5%).","jir_summary":"### Performance Overview\nOno Pharmaceutical Co., Ltd.'s consolidated financial results for 2025 (fiscal year ending March 2026) show sales of 486.9 billion yen (up 5.9% YoY), core operating profit of 112.7 billion yen (up 21.7% YoY), and net income attributable to owners of the parent of 90.4 billion yen (up 14.5% YoY). The solid results were driven by increased sales of key domestic and overseas products and higher royalty income. The outlook for 2026 suggests sales of 515.8 billion yen (down 11.8%), core operating profit of 137.1 billion yen (down 9.6%), and net income of 103.5 billion yen (down 14.5%).\n\n### Future Outlook and Key Points\nIn 2026, sales are expected to decline due to decreased sales of core products and increased competition, but progress in new development products and pipeline of candidates is anticipated. The company plans to promote efficiency in R&D and selling, general, and administrative expenses while expanding overseas operations and obtaining new drug approvals. Shareholder returns and capital policies will also be continued, aiming for long-term growth and improved profitability.","jir_financial_highlights":"Sales Revenue: 486.9 billion yen (Up 5.9% YoY)\nCore Operating Profit: 112.7 billion yen (Up 21.7% YoY)\nNet Income Attributable to Owners of the Parent: 90.4 billion yen (Up 14.5% YoY)","jir_category":"","jir_hashtags":"#OnoPharmaceutical, #EarningsReport, #JapanStocks","jir_key_figures":"Sales Revenue: 486.9 billion yen (up 5.9% YoY)\nCore Operating Profit: 112.7 billion yen (up 21.7% YoY)\nNet Income Attributable to Owners of the Parent: 90.4 billion yen (up 14.5% YoY)","jir_meta_title":"\u3010Ono Pharmaceutical\u30112025 Fiscal Year Results\uff5cSales of 486.9 billion yen +5.9%","jir_meta_description":"Ono Pharmaceutical's consolidated financial results for 2025 (fiscal year ending March 2026) show strong performance with sales of 486.9 billion yen, operating profit of 112.7 billion yen, and net income of 90.4 billion yen. Detailed forecast for 2026 included.","jir_og_title":"\u3010Ono Pharmaceutical\u30112025 Fiscal Year Results\uff5cSales of 486.9 billion yen +5.9%","jir_og_description":"Ono Pharmaceutical's 2025 fiscal year results show revenue of 486.9 billion yen, operating profit of 112.7 billion yen, and net income of 90.4 billion yen, with growth driven by various factors. Outlook covered as well.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":7530,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-45225","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n